Scienture Holdings, Inc. · NASDAQ:SCNX
Scienture — Investor Presentation (May 2026)
17 slides from Scienture's investor presentation, May 5, 2026
Slide 1: Scienture Holdings
3 Scienture Holdings We invest in creating better health outcomes NASDAQ: SCNX
Slide 2: Safe Harbor Statement and Non-GAAP Measures
Safe Harbor Statement and Non-GAAP Measures ‘The information set forth herein contains forward-looking statements within the federal secuites laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that 4o
Slide 3: Scienture Holdings, Inc | About Us
Scienture Holdings, Inc | About Us Scienture Holdings is a fully integrated pharmaceutical product group committed to providing greater value to patients, physicians, and caregivers through the development, commercialization, and distribution of innovative specialty products designed to meet unmet c
Slide 4: Leadership
Leadership Executive Management Shankar Hariharan, Ph.D. Executive Chairman & Co-CEO, Director Over 35 years of experience in Pharmaceutical Industry. Involved with development and commercialization of Celexa® (>$2B), Lexapro® ($4), Namenda® (>$2B), Megace ES® (>$100M). He has founded and has held b
Slide 5: Our Mission
Our Mission Our mission is to bring patients selectively designed drug product innovations through accelerated nuanced commercialization by channeling the power of technology platforms Beginnings Our founders identified critical gaps in care—challenging treatment paradigms, safety and efficacy limit
Slide 6: Prioritizing Patients.
ge . Prioritizing Patients. 8°: Scienture improving outcomes (a wholly owned subsidiary of Scienture Holdings, Inc.)
Slide 7: Delivering Better | Improving today’s medicines for a better tomorrow
Delivering Better™ | Improving today’s medicines for a better tomorrow We fuse our core capabilities to these cornerstones, delivering scientific and commercial solutions, addressing gaps in therapy treatment, and leading to better health outcomes. Scienture Chemistry Data-Driven Insights From R&D t
Slide 8: Product Portfolio
Product Portfolio Anticipated Early Animal Human Studies NDA/ BLA Anticipated Product | Indication Development _— Studies Phase 1 Phase 2 Phase 3 Timeline Launch Arbli™|CVS/Hypertension ETS Mar 2025 Q3.2025 Notneaied (Approved) (Launched) Oral suspension for geriatric and pediatric use tpl TS a ed ‘
Slide 9: Intellectual Property | USPTO Granted Patents and Pending Applications
Intellectual Property | USPTO Granted Patents and Pending Applications + Arbli™ (SCN-102) + Patent #: 11,890,273, Issue Date: February 6, 2024, titled “LOSARTAN LIQUID FORMULATIONS AND METHODS OF USE”, Expiration Date: October 7, 2041 + Patent # 12,156,869; Issue Date: December 3, 2024, titled “LOSA
Slide 10: Arbli (losartan potassium) Oral Suspension
Arbli™ (losartan potassium) Oral Suspension 10 mg / mL 165 mL bottle The first and only FDA approved liquid losartan formulation available in the US Market First and only liquid ARB | FDA Approved March 13, 2025 Successfully commercially launched Arbli™ in September 2025 Arbli™ (losartan potassium)
Slide 11: REZENOPY (Naloxone HCI) Nasal Spray, 10mg
REZENOPY™ (Naloxone HCI) Nasal Spray, 10mg The Highest FDA-approved Dose per nasal spray for Naloxone in the US market ‘The Maximum-Dose Naloxone Solution for your formulary | FDA Approved April 24, 2024; Commercial Launch June 2026 @ Highest Dose REZENOPY™ delivers 10mg naloxone— the highest FDA-ap
Slide 12: Commercial Operations | Strategy & Execution
Commercial Operations | Strategy & Execution A sound strategy in place for a robust coordinated commercial execution Prom nal + Branding + Patient+ HOP Narratives ~ = + Brand Institute Logo and Naming Development + Value Proposition Development y Data-Driven Insights + IQVANSPINPA Insights/DDD data
Slide 13: SCN-104 | Fixed Dose Injection Pen
SCN-104 | Fixed Dose Injection Pen Product Description Therapeutic Area Easy-to-use, multidose pen NS (Migraine) based delivery system for self Indicated for acute treatment of injection and increased ‘migraine headaches with or convenience. without aura and cluster headache episodes Value Propositi
Slide 14: SCN-106 | Biosimilar Product
SCN-106 | Biosimilar Product Product Description Therapeutic Area US Market Large Molecule Biosimilar CVS (hospital based) Total Addressable Market Size for CV use (IQVIA Feb 2026)-8636MM Value Proposition we Potential to be the First to Market Biosimilar for the brand product at an attractive price
Slide 15: SCN-107 | Extended-Release Injection
SCN-107 | Extended-Release Injection Product Description Microsphere based long-acting injection with immediate release ‘component. Value Proposition @ tial reduction to opioid usage following surgeries Therapeutic Area US Market NS (Post surgical pain) Total Addressable Market Size Indicated for po
Slide 16: Financial Model and Outlook
Financial Model and Outlook 2026 2027 2028 2029 2030 2031 Net Sales $ 63. $ 26.7 $ 59.1 $ 131.3 $ 225.0 $ 270.3 Gross Margin $ 5.6 $ 229 $ 514 $ 109.8 $ 188.9 $ 229.1 Gross Margin % 88% 86% 87% 84% 84%. 85% SG&A $ (0s) $ 130) $ (62) $ (74) $ (190) $ (21.0) Profit $ (4.9) $ 99 $ 35.2 $ 924 $ 169.9 $
Slide 17: Thank you!
Thank you! SCIENTURE HOLDINGS, INC. 20 Austin Blvd Commack, NY 11725 Phone: (866) 468-6535 Email: IR@Scienture.com Scienture Holdin
Scienture Holdings — Investor Presentation (May 2026) on 6ix